In total, 492 individuals with advanced KRAS and BRAF wt CRC were reviewed, 288 of whom were deemed to be ineligible per the exclusion criteria, leaving 204 patients (CET: n=100, mean age 64.2 years [SD 9.5] and BEV: n=104, 64.5 years [SD 8.7]) who were eventually included for study eligibility (Fig. 1). The gene discussed is KRAS; the disease is colorectal carcinoma.